wpeB.jpg (25751 bytes)

        216-844-3100

Home

 

The Carbatrol® Difference
Not all drug delivery systems are the same
Unlike the delivery systems used in other extended-release products, each Carbatrol® capsule is filled with 3 different types of timed-release beads. These beads dissolve and release medication into your bloodstream over a period of about 12 hours, making it possible for you to take your medicine once in the morning and again at night without having to worry about remembering to take it during a busy day.

The unique Carbatrol® delivery system is made up of:
  • 25% immediate-release beads, which release carbamazepine almost as soon as swallowed for rapid absorption and therapeutic blood levels
  • 40% extended-release beads, which dissolve gradually over 8 to 12 hours
  • 35% enteric-release beads, which dissolve farther along in the digestive system and help maintain optimal drug levels toward the end of the dosing period

Why the delivery system is important

Another extended-release carbamazepine, called Tegretol®-XR, has a different delivery system and comes in tablet rather than capsule form. Although these tablets also provide effective seizure control, they have a number of differences. They must be swallowed whole and cannot be opened and sprinkled on soft food, as Carbatrol® capsules can. Tegretol®-XR tablets must always be taken with food, while Carbatrol® can be taken with or without food. The amount of medicine released by the tablet can vary significantly, depending on how long the tablet remains in the stomach.1,2 The tablet may also pass through the digestive system without completely breaking down, leaving an undissolved shell or "ghost pill" in the patient's stool. Carbatrol® is free of all of these inconveniences.

References

1. Wilding IR, Davis SS, Hardy JG, et al. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. Br J Clin Pharmacol. 1991;32:573-579. 2. McLean AM, Wilding IR, Zhang Y. Pharmacoscintigraphic evaluation of controlled release carbamazepine in healthy volunteers [abstract]. Epilepsia. 1999;40(suppl 7):101.

Tegretol®-XR is a registered trademark of Novartis Pharmaceuticals Corporation.

Click on this link to go to the Carbatrol page 

Use the "back" function on your browser to return to this page.